Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Chronic Heart Failure

Free Subscription Articles published in Lancet Retrieve available abstracts of 34 articles: HTML format

Single Articles

April 2024
1. BUTLER J, Shah SJ, Petrie MC, Borlaug BA, et al
   Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
   Lancet. 2024 Apr 4:S0140-6736(24)00469-0. doi: 10.1016/S0140-6736(24)00469.
   PubMed     Abstract available
   
   
   
2. DONAL E, L'Official G, Istratoaie S
   Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
   Lancet. 2024 Apr 4:S0140-6736(24)00653-6. doi: 10.1016/S0140-6736(24)00653.
   PubMed    
   
   
   March 2024
3. KIKOINE J, Kilani N, Pitta-Gros B, Yerly P, et al
   Remote haemodynamic monitoring in patients with heart failure.
   Lancet. 2024;403:808.
   PubMed    
   
   
   
4. BRUGTS JJ, Aydin D, Clephas PRD, de Boer RA, et al
   Remote haemodynamic monitoring in patients with heart failure - Authors' reply.
   Lancet. 2024;403:808-809.
   PubMed    
   
   
   
5. KOMAMURA K, Iwase M
   Remote haemodynamic monitoring in patients with heart failure.
   Lancet. 2024;403:807-808.
   PubMed    
   
   
   February 2024
6. CAMPBELL P, Rutten FH, Lee MM, Hawkins NM, et al
   Heart failure with preserved ejection fraction: everything the clinician needs to know.
   Lancet. 2024 Feb 14:S0140-6736(23)02756-3. doi: 10.1016/S0140-6736(23)02756.
   PubMed     Abstract available
   
   
   November 2023
7. KHAN Y, Verhaeghe N, Devleesschauwer B, Cavillot L, et al
   Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review.
   Lancet. 2023;402 Suppl 1:S61.
   PubMed     Abstract available
   
   
   August 2023
8. WILKOFF BL, Filippatos G, Leclercq C, Gold MR, et al
   Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial.
   Lancet. 2023 Aug 24:S0140-6736(23)00912-1. doi: 10.1016/S0140-6736(23)00912.
   PubMed     Abstract available
   
   
   May 2023
9. ANGERMANN CE
   Remote pulmonary artery pressure monitoring in heart failure care: part of the new normal?
   Lancet. 2023 May 19:S0140-6736(23)01010-3. doi: 10.1016/S0140-6736(23)01010.
   PubMed    
   
   
   
10. BRUGTS JJ, Radhoe SP, Clephas PRD, Aydin D, et al
    Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial.
    Lancet. 2023 May 19:S0140-6736(23)00923-6. doi: 10.1016/S0140-6736(23)00923.
    PubMed     Abstract available
    
    
    April 2023
11. SCHLAICH MP, Bellet M, Weber MA, Bakris GL, et al
    Fluid retention and heart failure in the PRECISION trial - Authors' reply.
    Lancet. 2023;401:1335-1336.
    PubMed    
    
    
    
12. KOHAN DE, Heerspink HJL
    Fluid retention and heart failure in the PRECISION trial.
    Lancet. 2023;401:1335.
    PubMed    
    
    
    March 2023
13. HE J, Ouyang N, Guo X, Sun G, et al
    Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
    Lancet. 2023 Mar 2:S0140-6736(22)02603-4. doi: 10.1016/S0140-6736(22)02603.
    PubMed     Abstract available
    
    
    November 2022
14. MCDONAGH TA, Bromage DI, Cannata A
    Intravenous iron passes another endurance test in heart failure.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02180.
    PubMed    
    
    
    
15. KALRA PR, Cleland JGF, Petrie MC, Thomson EA, et al
    Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02083.
    PubMed     Abstract available
    
    
    
16. MEBAZAA A, Davison B, Chioncel O, Cohen-Solal A, et al
    Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02076.
    PubMed     Abstract available
    
    
    
17. 
    Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02074.
    PubMed     Abstract available
    
    
    August 2022
18. VADUGANATHAN M, Docherty KF, Claggett BL, Jhund PS, et al
    SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01429.
    PubMed     Abstract available
    
    
    
19. TUTTLE KR, Rangaswami J
    SGLT2 inhibitors as the bedrock of therapy for heart failure.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01584.
    PubMed    
    
    
    
20. CARTELLA I, Tavecchia GA, Quattrocchi G, Giannattasio C, et al
    A heart of iron: juvenile haemochromatosis presents with cardiac failure.
    Lancet. 2022;400:616.
    PubMed    
    
    
    April 2022
21. BECK-DA-SILVA L, Rohde LE
    Reduction of dietary sodium for heart failure: a step forward.
    Lancet. 2022;399:1361-1363.
    PubMed    
    
    
    
22. EZEKOWITZ JA, Colin-Ramirez E, Ross H, Escobedo J, et al
    Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial.
    Lancet. 2022;399:1391-1400.
    PubMed     Abstract available
    
    
    January 2022
23. SHAH SJ, Borlaug BA, Chung ES, Cutlip DE, et al
    Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.
    Lancet. 2022 Jan 31. pii: S0140-6736(22)00016.
    PubMed     Abstract available
    
    
    August 2021
24. KARWATH A, Bunting KV, Gill SK, Tica O, et al
    Redefining beta-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis.
    Lancet. 2021 Aug 27. pii: S0140-6736(21)01638.
    PubMed     Abstract available
    
    
    
25. LINDENFELD J, Zile MR, Desai AS, Bhatt K, et al
    Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01754.
    PubMed     Abstract available
    
    
    
26. CLELAND JGF, Pellicori P
    To master heart failure, first master congestion.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01914.
    PubMed    
    
    
    
27. 
    Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01921.
    PubMed     Abstract available
    
    
    July 2021
28. BROWN E, Heerspink HJL, Cuthbertson DJ, Wilding JPH, et al
    SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
    Lancet. 2021;398:262-276.
    PubMed     Abstract available
    
    
    May 2021
29. 
    Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
    Lancet. 2021;397:1625-1636.
    PubMed     Abstract available
    
    
    March 2021
30. FIGTREE GA, Vernon ST, Hadziosmanovic N, Sundstrom J, et al
    Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Lancet. 2021;397:1085-1094.
    PubMed     Abstract available
    
    
    February 2021
31. LANGLEY RE, Gilbert DC, Duong T, Clarke NW, et al
    Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
    Lancet. 2021;397:581-591.
    PubMed     Abstract available
    
    
    January 2021
32. VADUGANATHAN M, Fonarow GC, McMurray JJV, Solomon SD, et al
    Considering dose in pharmacological therapies for heart failure - Authors' reply.
    Lancet. 2021;397:275.
    PubMed    
    
    
    
33. SEEDAT Z, Itty K
    Considering dose in pharmacological therapies for heart failure.
    Lancet. 2021;397:274-275.
    PubMed    
    
    
    November 2020
34. PONIKOWSKI P, Kirwan BA, Anker SD, McDonagh T, et al
    Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32339.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.